QMS Medical Allied Services Ltd

QMS Medical Allied Services Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

QMS Medical Allied Services Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

QMS Medical Allied Services Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

QMS Medical Allied Services Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 15 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 February 2026, providing investors with the latest insights into the company’s performance and outlook.

QMS Medical Allied Services Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive price range. This change, driven primarily by adjustments in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a potential reappraisal of the stock’s price attractiveness amid a challenging sector backdrop and mixed returns relative to the broader market.

QMS Medical Allied Services Ltd., a micro-cap medical products distributor with a market capitalisation of ₹180.00 crores, reported a challenging third quarter for FY2026, with consolidated net profit declining 23.08% quarter-on-quarter to ₹2.40 crores in Q3 FY26 from ₹3.12 crores in Q2 FY26. On a year-on-year basis, the profit contraction was even more pronounced at 17.81%, falling from ₹2.92 crores in Q3 FY25. The stock, trading at ₹92.75, has gained 5.04% in the latest trading session, though it remains 18.64% below its 52-week high of ₹114.00.

QMS Medical Allied Services Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development suggests a potential shift towards a bearish trend, reflecting deteriorating momentum and long-term weakness in the stock’s price action.

QMS Medical Allied Services Ltd is rated Sell by MarketsMOJO, with this rating last updated on 04 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

QMS Medical Allied Services Ltd is rated Sell by MarketsMOJO. This rating was last updated on 04 Dec 2025, reflecting a shift from the previous Hold rating. However, the analysis and financial metrics discussed here represent the stock’s current position as of 28 January 2026, providing investors with the latest insights into its performance and outlook.

QMS Medical Allied Services Ltd is rated Sell by MarketsMOJO, with this rating last updated on 04 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 January 2026, providing investors with the latest insights into its performance and outlook.

QMS Medical Allied Services Ltd is rated Sell by MarketsMOJO. This rating was last updated on 04 Dec 2025. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest comprehensive analysis.

QMS Medical, a microcap player in the Healthcare Services sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment highlights evolving perspectives on the company’s quality, valuation, financial trends, and technical outlook amid a challenging market backdrop.